Medtronic plc (mdt)
MDT — Company Overview
Investors tracking MDT follow a Medical Devices name listed on NYQ within Healthcare.
| Ticker | MDT |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NYQ |
| Market cap | $109.98B |
| Last price | $85.92 |
| Size category | Large Cap |
MDT — Business Description
The business profile of Medtronic plc (MDT) reflects its role in Medical Devices. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories,…
Official website: https://www.medtronic.com.
MDT — Investment Thesis
Medtronic plc (MDT) attracts investors weighing Medical Devices fundamentals against current market pricing.
- Revenue is expanding at roughly 9.9% year-over-year (public data).
- Trailing P/E of 23.03× sits in a moderate band relative to high-growth peers.
- Forward P/E (13.40×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 3.4% adds an income component to total return.
- Equity market capitalization is approximately $109.98B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
MDT — Financial Health
MDT financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 13.2% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $4.63B supports balance-sheet flexibility.
| Trailing P/E | 23.03× |
| Forward P/E | 13.40× |
| Price / Sales | 3.02× |
| Price / Book | 2.22× |
| Gross margin | 65.3% |
| Operating margin | 22.0% |
| Profit margin | 13.2% |
| Return on equity | 9.8% |
| Debt / Equity | 58.21 |
| Free cash flow | $4.63B |
MDT — Growth Outlook
Growth outlook for Medtronic plc (MDT) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 9.9% suggests steady but measured expansion.
- Earnings growth of 18.3% year-over-year supports improving profitability.
- Price is 19.2% below the 52-week high.
- Shares trade 17.2% above the 52-week low — limited rebound so far.
MDT — Competitive Position
Medtronic plc (MDT) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $109.98B places MDT among large-cap peers.
- Gross margin near 65.3% may reflect pricing power or favorable mix.
MDT — Strengths
Strengths for Medtronic plc (MDT) inferred from public financial metrics:
- Revenue growth of 9.9% year-over-year.
- Earnings growth of 18.3% year-over-year.
- Gross margin of 65.3% supports competitive unit economics.
- Positive free cash flow ($4.63B).
- Dividend yield of 3.4% for income-oriented holders.
- Moderate leverage (debt/equity 58.21).
MDT — Weaknesses
Weaknesses and pressure points for Medtronic plc (MDT) based on available data:
Insufficient public data to assess this factor.
MDT — Opportunities
- Sustained revenue growth (9.9%) could support multiple expansion if margins hold.
- Trading 17.2% above the 52-week low — potential recovery if fundamentals stabilize.
- Dividend yield of 3.4% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
MDT — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
MDT — Summary
Medtronic plc (MDT) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $85.92 with market cap $109.98B. Trailing P/E 23.03×. Revenue grew 9.9% year-over-year per public data. Notable strengths include revenue growth of 9.9% year-over-year. For analyst estimates, ownership, and live news on MDT, upgrade to Vest Terminal Professional.
Medtronic plc FAQ
What does Medtronic plc (MDT) do?
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio…
What is MDT's P/E ratio?
Medtronic plc has a trailing P/E of 23.03× based on publicly available market data.
Does MDT pay a dividend?
Indicated dividend yield: 3.4%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MDT in?
Medtronic plc is classified in Healthcare (Medical Devices) on NYQ.
What is MDT's market capitalization?
Approximate market cap: $109.98B.
What are the main risks for MDT?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of MDT?
Potential positives include revenue growth of 9.9% year-over-year, earnings growth of 18.3% year-over-year.
Where can I get analyst estimates for MDT?
Consensus estimates, price targets, and detailed analyst data for Medtronic plc are available to Professional subscribers in Vest Terminal — not on this public summary page.